BioCardia, Inc. announced the completion of enrollment and dosing in the low dose cohort of its Phase I/II CardiALLO™ trial, which aims to treat patients with ischemic heart failure of reduced ...
Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...
First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure Trial enrolled 11 participants in ...
BioCardia announces data verification completion for Phase 3 CardiAMP HF study on heart failure treatment, with results due March 30, 2025. BioCardia, Inc. has completed source data verification and ...
WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...
Alector, Inc. is a pre-revenue biotech reset after Latozinemab’s Phase 3 failure, now trading at a deep discount. Nivisnebart, targeting Alzheimer’s, is ALEC’s next major catalyst; interim Phase 2 ...
The Phase 2b SEISMiC Extension Study showed istaroxime significantly improved systolic blood pressure over six hours compared to placebo. Windtree plans to present detailed study findings, including ...
The half-life of CK-586 was observed to be in the range of 14 to 17 hours. The data support the advancement of CK-586 to a Phase 2 trial for heart failure with preserved ejection fraction, expected to ...
BMS and AstraZeneca said the IDMC does not believe the ACS trial will meet its primary endpoint. Image credit: Piyaset / Shutterstock.com. Bristol Myers Squibb (BMS) and AstraZeneca have decided to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results